The COVID-19 Clinical Landscape and Its Impact on Clinical Research and the Biopharmaceutical Sector

About the white paper

The COVID-19 pandemic has dramatically disrupted the global community and economy. While new development programs for COVID-19 spring up globally, the clinical research paradigm for study execution is being changed, and our industry is being forced to adapt and find new creative ways to further clinical research in all areas, not just for COVID-19. 

In this white paper, we partnered with Informa Pharma Intelligence to bring you the latest information on this pandemic and will cover the following key areas:

• Status of COVID-19 pandemic – the global spread
• Our industry’s response to combat COVID-19 and new projects underway
• The pandemic’s impact on ongoing “traditional” research
• How CROs and Sponsors are adapting to trial conduct in the new environment
• The Human Element – Considering Patient Enrollment

Complete the form to get the white paper!